🇺🇸 FDA
Patent

US 11332743

Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof

granted A61KA61K31/7105A61K31/713

Quick answer

US patent 11332743 (Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof) held by Alnylam Pharmaceuticals, Inc. expires Mon May 12 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Alnylam Pharmaceuticals, Inc.
Grant date
Tue May 17 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 12 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
26
CPC classes
A61K, A61K31/7105, A61K31/713, A61P, A61P3/06